Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1997 2
2011 1
2013 2
2014 1
2015 2
2016 2
2018 4
2019 2
2021 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Ityokumbul
Page 1
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. Patel JD, et al. J Clin Oncol. 2013 Dec 1;31(34):4349-57. doi: 10.1200/JCO.2012.47.9626. Epub 2013 Oct 21. J Clin Oncol. 2013. PMID: 24145346 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplat …
PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performan …
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, Brig R, Danso M, Yuan Y, Abbattista A, Noonan K, Niyazov A, Chakrabarti J, Czibere A, Symmans WF, Telli ML. Litton JK, et al. Oncologist. 2023 Oct 3;28(10):845-855. doi: 10.1093/oncolo/oyad139. Oncologist. 2023. PMID: 37318349 Free PMC article. Clinical Trial.
Deaggregation of cellulose macrofibrils and its effect on bound water.
Maloney T, Phiri J, Zitting A, Paajanen A, Penttilä P, Ceccherini S. Maloney T, et al. Carbohydr Polym. 2023 Nov 1;319:121166. doi: 10.1016/j.carbpol.2023.121166. Epub 2023 Jun 29. Carbohydr Polym. 2023. PMID: 37567690 Free article.
This led to a large jump in mesoscale swelling, from 0.9 to 2.5 mL/g, and surface area, from 400 to 1000 m(2)/g. This deaggregation was confirmed with X-ray scattering and solute exclusion. ...The hydrated surface area for the samples was in the range 1200-1400 m(2) …
This led to a large jump in mesoscale swelling, from 0.9 to 2.5 mL/g, and surface area, from 400 to 1000 m(2)/g. This deaggregation w …
"Cervical cancer screening: awareness is not enough". Understanding barriers to screening among women in West Cameroon-a qualitative study using focus groups.
Datchoua Moukam AM, Embolo Owono MS, Kenfack B, Vassilakos P, Petignat P, Sormani J, Schmidt NC. Datchoua Moukam AM, et al. Reprod Health. 2021 Jul 9;18(1):147. doi: 10.1186/s12978-021-01186-9. Reprod Health. 2021. PMID: 34243778 Free PMC article.
Thematic analysis was used, and barriers were classified according to the three-delay model of Thaddeus and Maine. RESULTS: In total, six FGs with 43 participants (31 women and 12 men) were conducted. ...
Thematic analysis was used, and barriers were classified according to the three-delay model of Thaddeus and Maine. RESULTS: In total, …
Direct effects of leisure-time physical activity on walking speed.
Haight TJ, van der Laan MJ, Manini T, Tager IB. Haight TJ, et al. J Nutr Health Aging. 2013;17(8):666-73. doi: 10.1007/s12603-013-0024-9. J Nutr Health Aging. 2013. PMID: 24097020 Free article.
., age75 years, diabetes, CVD) at each visit. RESULTS: Walking speed was significantly greater (0.74, 0.75 m/s in women and men, respectively) if subjects experienced LTPA 22.5 Mets/week and > median LNFAT, compared with <22.5 Mets/week and median LNFAT (0.68, 0.69 …
., age75 years, diabetes, CVD) at each visit. RESULTS: Walking speed was significantly greater (0.74, 0.75 m/s in women and men, resp …
25 results